 |
年间契约型资讯服务
商品编码
1524359
肝细胞癌：KOL 见解Hepatocellular Carcinoma - KOL Insight |
||||||
价格
简介目录
本报告分析了肝细胞癌（HCC）治疗环境的进展状况。领先的KOL就Roche Tecentriq（atezolizumab）和 Avastin（(bevacizumab）的整合作为不可切除 HCC 的一线治疗提供了见解，此外，AstraZeneca的Imfinzi（durvalumab）和Imjudo（tremelimumab）对于有使用Avastin禁忌的患者的使用增加，以及Bristol Myers Squibb的Opdivo（nivolumab）联合Uervoy（ipilimumab）作为一线治疗的潜力。了解新疗法的新兴作用以及对临床实践和药物开发的影响。
本报告回答的关键问题：
- KOL 使用Roche Tecentriq（atezolizumab）和Avastin（(bevacizumab）联合疗法治疗肝细胞癌效果如何？自IMbrave050资料以来，KOL在辅助设定中是否使用过这种组合？
- 专家认为Tecentriq和Avastin合併治疗取得进展后或不适合合併治疗的患者较适合使用哪种药物？
- AstraZeneca的 Imfinzi（durvalumab）和 Imjudo（tremelimumab）核准后的使用情况如何？如何将 KOL 纳入治疗演算法？
- KOL 如何使用 TKI Nexavar（sorafenib；Bayer）和 Lenvimalenvatinib；Eisai/Merck KGaA）以及如何在治疗演算法中定位？
- KOL 对 Stivarga（regorafenib；Bayer）、Cabometyx（cabozantinib；Exelixis/Ipsen）、Cyramza（ramucirumab；Eli Lilly）和 HCC 等药物的相对地位有何看法？
- KOL 认为哪些管线处理方法最有前景？
- 未来五年，什么会为肝细胞癌治疗典范带来最大的改变？
本报告调查的主要品牌
|
|
调查目标公司
|
|
目录
执行摘要
目前/未来的治疗演算法
研究目的
检查点抑制剂
- 核准的药物
- Tecentriq（atezolizumab；Roche）、Avastin（bevacizumab；Roche）
- Imfinzi（durvalumab；AstraZeneca）、Imjudo（tremelimumab；AstraZeneca）
- Opdivo（nivolumab；BMS/Ono Pharmaceutical）、Yervoy（ipilimumab；BMS）
- Keytruda（pembrolizumab；Merck KGaA）
- 研究药物
- Tevimbra/Tizveni (tislelizumab; BeiGene)
- Camrelizumab and rivoceranib (Jiangsu Hengrui Medicine/Elevar Therapeutics)
- Nofazinlimab (CStone Pharmaceuticals/3SBio) and Loqtorzi (toripalimab; Coherus BioSciences/Junshi Biosciences)
酪胺酸激酶抑制剂
- 核准的药物
- Nexavar（sorafenib；Bayer）
- Lenvima（lenvatinib；Eisai/Merck KGaA）
- Cabometyx（cabozantinib；Exelixis/Ipsen）
- Stivarga（regorafenib；Bayer）
VEGFR抑制剂
- 核准的药物
- Cyramza（ramucirumab；Lilly）
其他作用机转
- 研究药物
- Namodenoson（Can-Fite BioPharma）
- Tilagolumab（Roche）
- Rivmoniplimab、budigalimab（AbbVie）
- Kasdozokitug（Coherus BioSciences）
- Fostrox（fostroxacitabine brapamide；Medivir）
- Amezalpat（TPST-1120；Tempest Therapeutics）
未来治疗趋势
- 主要考虑因素：摘要
附录
- KOL 详细信息
- 美国的 KOL
- 欧洲的 KOL
简介目录
Explore the evolving landscape of hepatocellular carcinoma (HCC) treatment. Leading KOLs provide insights on the consolidation of Roche's Tecentriq (atezolizumab) plus Avastin (bevacizumab) as the first-line treatment for unresectable HCC, the rising use of AstraZeneca's Imfinzi (durvalumab) plus Imjudo (tremelimumab) for patients contraindicated for Avastin, and the potential of Bristol Myers Squibb's Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment. Gain an understanding of the emerging role of novel therapies and the implications for clinical practice and drug development.
Key questions answered:
- How do KOLs use Roche's Tecentriq (atezolizumab) plus Avastin (bevacizumab) in HCC? Have KOLs used the combination in the adjuvant setting since the data from IMbrave050?
- Which agents do the experts prefer to use after Tecentriq plus Avastin progression or in patients unsuitable for the combination?
- What has the uptake of AstraZeneca's Imfinzi (durvalumab) and Imjudo (tremelimumab) been like since its approval? How do KOLs place it in the treatment algorithm?
- How do KOLs use TKIs Nexavar (sorafenib; Bayer) and Lenvima (lenvatinib; Eisai/Merck & Co.), and how are they placed in the treatment algorithm?
- What do KOLs think of agents such as Stivarga (regorafenib; Bayer), Cabometyx (cabozantinib; Exelixis/Ipsen) and Cyramza (ramucirumab; Eli Lilly) and their relative positioning for HCC?
- Which pipeline therapies do KOLs find the most promising and why?
- What will be the most significant changes to the HCC treatment paradigm over the next five years?
Key brands covered in this report:
|
|
Companies:
|
|
Table of Contents
Executive summary
Current and future treatment algorithm
Research objectives
Checkpoint inhibitors
- Approved drugs
- Tecentriq (atezolizumab; Roche) and Avastin (bevacizumab; Roche)
- Imfinzi (durvalumab; AstraZeneca) and Imjudo (tremelimumab; AstraZeneca)
- Opdivo (nivolumab; BMS/Ono Pharmaceutical) and Yervoy (ipilimumab; BMS)
- Keytruda (pembrolizumab; Merck & Co.)
- Pipeline drugs
- Tevimbra/Tizveni (tislelizumab; BeiGene)
- Camrelizumab and rivoceranib (Jiangsu Hengrui Medicine/Elevar Therapeutics)
- Nofazinlimab (CStone Pharmaceuticals/3SBio) and Loqtorzi (toripalimab; Coherus BioSciences/Junshi Biosciences)
Tyrosine kinase inhibitors
- Approved drugs
- Nexavar (sorafenib; Bayer)
- Lenvima (lenvatinib; Eisai/Merck & Co.)
- Cabometyx (cabozantinib; Exelixis/Ipsen)
- Stivarga (regorafenib; Bayer)
VEGFR inhibitors
- Approved drugs
- Cyramza (ramucirumab; Lilly)
Other mechanisms of action
- Pipeline drugs
- Namodenoson (Can-Fite BioPharma)
- Tiragolumab (Roche)
- Livmoniplimab and budigalimab (AbbVie)
- Casdozokitug (Coherus BioSciences)
- Fostrox (fostroxacitabine bralpamide; Medivir)
- Amezalpat (TPST-1120; Tempest Therapeutics)
Future treatment trends
- Key insights summary
Appendix
- KOL details
- KOLs from the USA
- KOLs from Europe
02-2729-4219
+886-2-2729-4219
